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Summary The effect of Photofrin-based photodynamic therapy (PDT) and adjuvant treatment with serum vitamin D3-binding protein-derived
macrophage-activating factor (DBPMAF) was examined using a mouse SCCVII tumour model (squamous cell carcinoma). The results show
that DBPMAF can markedly enhance the curative effect of PDT. The most effective DBPMAF therapy consisted of a combination of
intraperitoneal and peritumoral injections (50 and 0.5 ng kg-' respectively) administered on days 0, 4, 8 and 12 after PDT. Used with a PDT
treatment curative to 25% of the treated tumours, this DBPMAF regimen boosted the cures to 100%. The DBPMAF therapy alone showed no
notable effect on the growth of SCCVII tumour. The PDT-induced immunosuppression, assessed by the evaluation of delayed-type contact
hypersensitivity response in treated mice, was greatly reduced with the combined DBPMAF treatment. These observations suggest that the
activation of macrophages in PDT-treated mice by adjuvant immunotherapy has a synergistic effect on tumour cures. As PDT not only
reduces tumour burden but also induces inflammation, it is proposed that recruitment of the activated macrophages to the inflamed tumour
lesions is the major factor for the complete eradication of tumours.
Keywords: photodynamic therapy; macrophage-activating factor; binding protein-derived macrophage-activating factor; Photofrin;
tumour cure; immunosuppression; mouse SCCVII tumour
Photodynamic therapy (PDT) is becoming a treatment of choice
for several types of solid cancers. Further development will prob-
ably broaden its use in the control ofmalignant and non-malignant
disease (Fisher et al, 1995). For improved efficacy of PDT for
solid cancers, it is important to have a more complete under-
standing ofthe mechanism oftumour eradication by this modality
in order to develop strategies for amplifying its curative potential.
One element that deserves increased attention is the role of PDT-
induced host response in the anti-tumour effect. Its dominant
manifestation is a strong acute inflammatory reaction the integral
part ofwhich is the accumulation ofnon-specific immune-effector
cells (neutrophils, monocytes/macrophages, mast cells) at the
treated site (Krosl et al, 1995; Korbelik and Krosl, 1996). There
are indications that the tumoricidal activity of these activated
inflammatory cells makes an essential contribution to the anti-
tumour effect ofPDT (Korbelik, 1996; Korbelik and Krosl, 1996).
Increased macrophage activity was demonstrated after PDT in
vitro and in vivo (Yamamoto et al, 1991, 1992; Krosl et al, 1995).
It was also reported that macrophages release tumour necrosis
factor alpha (TNF-ox) following PDT treatment (Evans et al, 1990)
and preferentially destroy PDT-treated tumour cell targets
(Korbelik and Krosl, 1994). Moreover, the macrophage activation
may constitute the first step in the inflammation-induced immune
development process directed against a PDT-treated tumour. We
have recently shown that the contribution of immune reaction
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induced after PDT treatment of mouse EMT6 sarcoma is essential
for preventing the recurrence ofthis tumour (Korbelik et al, 1996;
Korbelik, 1996). Given the major role of macrophages in the
anti-tumour effect of PDT, it seems worthwhile to explore the
potential of immunotherapy treatment targeting these cells as an
adjuvant to PDT.
The inflammation-induced creation of a potent macrophage-
activating factor derived from serum vitamin D3 binding protein
(DBP; the human protein is known as group-specific component
or Gc protein) was recently described (Yamamoto and Homa,
1991; Naraparaju and Yamamoto, 1994; Yamamoto and
Naraparaju, 1996a). This process, triggered by the degradation
products of membrane lipids (i.e. lysophospholipids) of inflamed
cells, involves the removal of galactose and sialic acid residues
from the DBP by membranous f-galactosidase of inflammation-
primed B cells and the Neu-] sialidase of T cells. The resulting
macrophage-activating factor is a protein with N-acetylgalac-
tosamine as the remaining sugar (Yamamoto and Homa, 1991;
Yamamoto and Naraparaju, 1996a). Thus, DBP is a precursor for
the macrophage-activating factor. Treatment of mouse DBP or Gc
protein (human DBP) with immobilized P-galactosidase and siali-
dase generated extremely high-titred macrophage-activating
factors, DBPMAF or GcMAF, respectively (Yamamoto and
Homa, 1991; Yamamoto and Naraparaju, 1996a). The phagocytic
and superoxide-generating capacities ofmacrophages were shown
to be greatly enhanced (3-, 7- and 15-fold respectively) by minute
doses of GcMAF (10 pg per mouse) or DBPMAF (50 pg per
mouse)(Yamamoto and Homa, 1991; Naraparaju and Yamamoto,
1994; Yamamoto and Naraparaju, 1996a).
Ourpreliminary studies indicate that GcMAF treatment is effec-
tive in augmenting the response of mouse tumours to PDT
(Korbelik et al, 1995). However, optimized treatment schedules
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required the repeated administration of GcMAF. In such cases,
mice may develop antibodies against this human protein and thus
diminish its effectiveness. Therefore, DBPMAF was prepared
from the mouse DBP, and its effectiveness as an adjuvant to PDT
was examined in this study.
MATERIALS AND METHODS
Tumour model and photodynamic treatment
Squamous cell carcinoma SCCVII (Suit et al, 1985), a poorly
immunogenic mouse tumour, was grown in 8-12-week-old
syngeneic C3H/HeN mice. It was maintained by bi-weekly intra-
muscular passage (Krosl et al, 1995). For experiments, tumours
were implanted subcutaneously on the lower dorsum of the mice
and grown until they reached 5-6 mm in the largest diameter.
The photosensitizer, Photofrin, porfimer sodium (QLT Photo-
Therapeutics, Vancouver, BC, Canada), was administered intra-
venously at 10 mg kg-' 24 h before treatment with 630 ± 10 nm
light. The light was delivered by surface illumination using a
model A5000 tunable light source supplied with a 1-kW xenon
bulb (Photon Technology International) through a 5-mm core
diameter liquid light guide (2000A, Luminex, Germany). The
power density at the treatment area, which encompassed the
tumour and 1-1.5 mm ofthe surrounding skin, was approximately
130 mW cm-2. During the light treatment, the mice were restrained
without anaesthesia in specially designed holders. Mice were
observed for up to 91 days for the assessment of tumour cure or
regrowth, and three orthogonal tumour diameters were measured
every second day. No sign of tumour at 90 days after PDT quali-
fied as the cure.
DBPMAF preparation and administration
The procedure for preparation of the enzymatically generated
macrophage-activating factors, DBPMAF and GcMAF, was
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Figure 1 The effect of single or multiple DBPMAF treatments on the SCCVII
tumour cure rate by Photofrin-based photodynamic therapy. Mice bearing
SCCVII tumours were given Photofrin (10 mg kg-', i.v.) and treated with 150
J cm-2 light 24 h later. DBPMAF was given intraperitoneally (50 ng kg-')
immediately after the end of light treatment (day 0) and thereafter at 4-day
intervals
described in detail elsewhere (Yamamoto and Homa, 1991;
Yamamoto and Naraparaju, 1996a). Briefly, mouse DBP (mDBP)
and Gc protein werepurifiedby 25-hydroxyvitamin D-affinity chro-
matography (Link et al, 1986) from mouse and human plasma
respectively. Incubation of mDBP or Gc protein (1 ,ug each) with
immobilized0-galactosidase and sialidase (0.1 U ml-') by tumbling
motion at 37°C for I h yielded extremely potent macrophage-
activating factors. The Limulus amoebocyte lysate assay was
routinely performed to assure that all media, protein and macro-
phage-activating factors are free oflipopolysaccharide (LPS).
For the treatment of mice, the original DBPMAF (or GcMAF)
stock solution was diluted in a 5% dextrose solution to 10 ng ml-',
so that 0.1 ml can be injected into a20-g mouse for a dose of50 ng
kg-'. The routes ofDBPMAF administration tested were intraperi-
toneal (i.p.), intravenous (i.v.) and peritumoral (p.t.). For the peri-
tumoral administration, the tumour was lifted and DBPMAF
slowly injected under the tumour using a 26-gauge needle. When
the treated tumour became impalpable, the DBPMAF solution was
injected subcutaneously as close as possible to the original tumour
site. Care was taken not to lose the injected solution through the
needle track.
In order to identify the most effective protocol for DBPMAF
treatment adjuvant to PDT, experiments were designed to deter-
mine the optimum route of administration, number of DBPMAF
treatments and their timing relative to PDT. In most experiments,
32 mice were inoculated from a common suspension of SCCVII
tumour cells (1 x 106 cells 0.03 ml-' per mouse) and then randomly
allocated into four treatment groups, each consisting ofeight mice.
One of the treatment groups was treated with PDT only in all
cases. During the course of the study, it was confirmed that the
solvent control treatment regimens with 5% dextrose (not
containing DBPMAF) had no observable effect on the response of
PDT-treated tumours. In the majority ofexperiments with the PDT
dose of 150 J cm-2, the injections of control solvent were not
included in the PDT-only group. Rather, the results for PDT-only
response were pooled from all these experiments and averaged to
enhance the values in the statistical analysis. In the presentation of
the results, these averaged values for the PDT-only group were
used for the comparison of the effects of various adjuvant
DBPMAF regimens. Statistical analysis of the data was based on
the log-rank test.
Delayed-type contact hypersensitivity (DTH) assay
The procedure was similar to that described by Lynch et al (1989).
Mice were sensitized to DTH by applying 35 jtl of 0.5% 2,4-dini-
trofluorobenzene (DNFB) in a 4:1 mixture of acetone and olive oil
on a shaved skin on the lateral side. Five days later the mice were
challenged by applying 15 gl of the DNFB solution to the right
rear footpad. The extent of footpad swelling was determined 24 h
later by measuring the difference in the thickness of the footpad
using a dial micrometer. In these experiments, the PDT light dose
was 240 J cm-2 (24 h after Photofrin was administered at 10 mg
kg-', i.v.), while DBPMAF (50 ng kg-' i.p. plus 0.5 ng kg-' p.t.)
was given on days 0, 4 and 8 after PDT. The initial treatment with
DNFB (sensitization) was at 4 days after photodynamic light treat-
ment, while the DNFB challenge and footpad swelling measure-
ments were at 9 and 10 days after PDT respectively. Individual
treatment groups consisted of 6-8 mice. The data are presented as
means from three independent experiments. Student's t-test was
used for the statistical analysis of these data.
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Figure 2 The effect of different routes of DBPMAF administration used as
adjuvant to photodynamic therapy of SCCVII tumours. Tumour-bearing mice
were treated with PDT as described in Figure 1. DBPMAF was given on days
0, 4, 8 and 12 after PDT. The DBPMAF dose, given by different routes of
administration, was 50 ng kg-', except for peritumoral treatment in i.p. plus
p.t. combination, which was 0.5 ng kg-'. Compared with PDT only *P<0.02;
**P<0.0005
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Figure 3 The effect of different timing of the onset of DBPMAF treatments
used in combination with photodynamic therapy of SCCVII tumours. Mice
bearing SCCVII tumours were treated with PDT as described in Figure 1.
DBPMAF (50 ng kg-', i.p. plus 0.5 ng kg-', p.t.) was given four times spaced
at 4-day intervals, and was initiated either 1 day before PDT, immediately
after PDT, or 1 day after PDT. Also shown is the response to PDT of tumour-
bearing mice that received the treatment with 5% dextrose equivalent to the
DBPMAF regimen on days 0, 4, 8 and 12 after PDT
RESULTS
Therapy of SCCVII tumour with PDT and DBPMAF
Photodynamic treatment, consisting of the administration of
Photofrin (10 mgkg-', i.v.) to SCCVII tumour-bearing mice followed
24 h later by tumour-localized exposure to 150 J cm-2 of 630-nm
light, was very close to the curative threshold. All treated tumours
blackened and became impalpable between 1 and 2 days after the
light delivery. This was followed by the recurrence of tumours 2-3
weeks later (Figure 1). The effect of single or multiple DBPMAF
treatments (50 ng kg-', i.p.), given at 4-day intervals and started
immediately after PDT, is shown in the same figure. Both regimens
with multiple DBPMAF treatments were effective in improving the
tumour response to PDT (P<0.02). The effect with single DBPMAF
treatment was not statistically significant. It was also noted that six
DBPMAF treatments were no more beneficial than four treatments.
Photofrin (10 mg kg-'); 240 J cm2
20
Time after PDT (days)
Figure 4 The effect of DBPMAF treatment on the response of SCCVII
tumours to partially curative photodynamic therapy. Mice bearing SCCVII
tumours were given Photofrin (10 mg kg-', i.v.) and treated with 240 J cm-2
light 24 h later. DBPMAF treatment (50 ng kg-1, i.p. plus 0.5 ng kg-', p.t.) was
given at days 0, 4, 8 and 12 relative to PDT
Using the four DBPMAF treatment schedule, the effectiveness
ofdifferent routes ofadministration was examined next (Figure 2).
It is evident that a combined treatment, consisting of intraperi-
toneal and peritumoral injections (50 and 0.5 ng kg-' respectively)
resulted in the most pronounced enhancement of PDT-based anti-
tumour effect. Unlike GcMAF treatment ofEhrlich ascites tumour
(Koga et al, 1996), the DBPMAF treatment had no obvious effect
on the solid SCCVII tumour in the absence of PDT. For instance,
at 14 days after implantation, the sizes oftumours in the DBPMAF
non-treated group, the group with DBPMAF administered 8 days
after tumour implant (otherwise the time of PDT treatment) and
the group with DBPMAF administered 2 days after implant (when
the tumour mass was very small, as is the case with reduced
tumour burden after PDT) were 339 ± 28, 340 ± 62 and 322 ± 127
(mm3 ± s.d.) respectively; DBPMAF was in this case administered
both i.p. and p.t. as described in Figure 2. Similar results were
obtained for the treatment of SCCVII tumours with GcMAF alone
(data not shown).
It was also examined whether the initiation of DBPMAF
therapy immediately following photodynamic light treatment is
more beneficial than the regimens commencing either 1 day before
or 1 day after PDT (Figure 3). It can be seen that the latter two
DBPMAF regimens resulted in lower cure rates, but the overall
difference between the three regimens was not statistically signifi-
cant. Also shown in Figure 3 is the response of a control PDT
group, which (instead of DBPMAF therapy) received an equiva-
lent treatment regimen of i.p. and p.t. injections of 5% dextrose.
The results confirm that these injections per se have no significant
effect on tumour response.
Fully curative effect by PDT combined with DBPMAF
Cures with approximately 25% ofSCCVII tumours treated by PDT
alone can be achieved by increasing the light dose to 240 J cm-2. In
this case, the adjuvant DBPMAF therapy, given at its optimized
regimen, attained a fully curative effect (Figure 4). The difference
between the two groups is statistically significant (P<0.001). With
this PDT plus DBPMAF combination, visible signs of acute
inflammatory reaction (oedema, fever) were markedly enhanced
and lasted for up to 2 weeks.
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Figure 5 The effect of GcMAF treatment on the cure rate of SCCVII tumours
by photodynamic therapy. Mice bearing SCCVII tumours were treated with
PDT as described in Figure 1. GcMAF treatment, administered either at 50
ng kg- i.p. plus 0.5 ng kg-' p.t. or at 5 ng kg-' i.p. plus 0.05 ng kg-' p.t., was
given at days 0, 4, 8 and 12 relative to PDT
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Figure 6 The effect of PDT and DBPMAF treatment of SCCVII tumour-
bearing mice on the delayed-type contact hypersensitivity (DTH) response in
the hosts. The DTH response was induced by the sensitization with 0.5%
2,4-dinitrofluorobenzene (DNFB), followed 5 days later by the challenge with
the same DNFB solution applied to the right rear footpad of the mice. The
footpad swelling was measured 24 h after the challenge. The PDT treatment
and DBPMAF therapy of SCCVII tumour-bearing mice was as described in
Figure 4, except for omitting the DBPMAF administration on day 12 after
PDT. The DNFB challenge was applied on day 9 after PDT. Bars represent
s.d. (interexperimental variation). The values for the two groups are
statistically different (P<0.025)
Adjuvant activity of GcMAF combined with PDT
The comparative evaluation of GcMAF used as the adjuvant to
PDT instead ofDBPMAF is shown in Figure 5. Although a signif-
icant enhancement of PDT response was obtained with both
GcMAF doses, i.e. 50 ng kg-' i.p. plus 0.5 ng kg-' p.t. and 5 ng kg-'
i.p. plus 0.05 ng kg-' p.t. (P<0.0025 and P<0.05 respectively), the
effect was apparently less pronounced than with DBPMAF.
The effect of DBPMAF on PDT-induced
immunosuppression
Since the immunosuppressive effects of PDT on the cellular level
were examined in our earlier studies (Yamamoto et al, 1991,
1992), in this work we examined the immune status of the whole
animal by using the standard DTH assay. The induction of
immunosuppression by SCCVII tumour treatment with PDT
alone, or combined with DBPMAF therapy, was examined. The
results for DTH response using the hapten DNFB (Figure 6)
demonstrated that the DBPMAF therapy markedly diminished the
immunosuppression induced in mice by the PDT treatment of
SCCVII tumour. The DBPMAF therapy alone showed no signifi-
cant effect on the DTH response of tumour-free mice (data not
shown). Since the tumours (if not PDT treated) become too large
before the time ofDTH assessment, it was not possible to evaluate
the effect of DBPMAF alone on the DTH response of tumour-
bearing mice.
DISCUSSION
The results of this study demonstrate that the response of SCCVII
tumour to Photofrin-based PDT can be markedly improved by
macrophage-directed immunotherapy using mouse DBPMAF. The
most beneficial DBPMAF therapy regimen for the combined
application with PDT consisted of four treatments given 4 days
apart, started immediately following photodynamic light delivery,
i.e. on days 0, 4, 8 and 12 relative to PDT. The most effective was
a combination of intraperitoneal and peritumoral (subtumoral)
DBPMAF injections given on each of the treatment days. The
rationale for staging multiple DBPMAF injections at 4-day inter-
vals comes from earlier studies (Yamamoto et al, 1988), which
demonstrated that the half-life of the activated state of macro-
phages is about 5-6 days. Since PDT induces inflammation,
macrophages activated by the systemic DBPMAF administration
are presumably chemotactically recruited to the PDT-treated
lesions (Korbelik, 1996). Additionally, peritumoral DBPMAF
injection facilitates in situ macrophage activation.
No further benefit was observed with increasing the DBPMAF
dose five times higher than that depicted in Figures 1-4; the
tumour cure rates, in fact, decreased (data not shown). It appears,
therefore, that overexposure to DBPMAF results in macrophage
deactivation. This is consistent with our in vitro results showing
that macrophage activation was reduced as dosages of this agent
increased over the optimum level (N Yamamoto, unpublished
results).
DBPMAF and GcMAF can be generated only from the glycosy-
lated DBP. They are highly conserved proteins. The amino acid
sequence of mouse DBP is 78% identical to human Gc and 91%
identical to rat DBP (Cooke and Haddad, 1989). The DBP protein
of all species carries only one oligosaccharide near the C-terminal.
Gcl, one of the major Gc isoforms, is 100% glycosylated. In
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contrast, only 10% of mouse DBP molecules are glycosylated
(Yamamoto and Naraparaju, 1996a). As non-glycosylated DBP
cannot be converted into DBPMAF, our mouse DBPMAF prepara-
tion contained the active form in only 10% of the total protein.
Nevertheless, the DBPMAF treatment was, in the present study,
more effective in potentiating the anti-tumour effect of PDT than
the equivalent GcMAF therapy. Such finding may be explained by
the possibility that mice can develop antibodies against the human
protein (GcMAF), which would reduce its effectiveness with
regimens involving multiple administration of this agent over
protracted time intervals. Commercial availability of interspecies
antibodies against Gc protein suggests that interspecific antibodies
are raised against non-homologous amino acid sequences of DBP.
Although the induction of immunosuppression by PDT would
have the potential of impairing the production of antibodies to
GcMAF in treated mice, this can be abrogated by the reversal
of the immunosuppressive effect following treatment with
macrophage-activating factor adjuvant to PDT (Figure 6).
In early clinical studies, multiple weekly administrations of
GcMAF alone produced excellent responses in a variety of human
cancers (N. Yamamoto et al, unpublished results), with no signs of
side-effects (Naraparaju et al, 1996). Given as a single modality,
this agent appears to be more effective against slow-growing
human tumours than against rapid-growing solid mouse tumours.
However, non-solid mouse tumours are sensitive to GcMAF
therapy. All mice transplanted with 105 Ehrlich ascites tumour cells
and administered GcMAF (100 ng per mouse) on days 0 and 4 (or
days 4 and 8) after transplantation survived over 65 days, whereas
all GcMAF-untreated mice died at 13 ± 3 days (Koga et al, 1996).
The mechanism of the potentiation of tumour response to PDT
by DBPMAF (GcMAF) features enhanced participation of the
host in the eradication of treated cancer. DBPMAF and GcMAF
were shown to activate macrophages, monocytes and other phago-
cytes (oesteoclasts, microglial cells, etc.) (Yamamoto and
Naraparaju, 1996b), but will not directly stimulate B and T cells
(Naraparaju and Yamamoto, 1994). In addition to markedly
enhancing the phagocytic and superoxide-generating capacities of
macrophages (referred to in the introduction), the macrophage
counts dramatically increase following DBPMAF or GcMAF
treatment (Yamamoto et al, 1994). This mitogenic effect suggests
that the expansion of macrophage populations from progenitors
that are not terminally differentiated may also be induced.
Therefore, it appears likely that macrophages, activated both
systemically and locally by DBPMAF therapy combined with
PDT, become more effectively involved in killing cancerous cells,
as well as in phagocytosis of tumour cell debris. The fact that an
optimized DBPMAF treatment regimen calls for repeated injec-
tions extending to 12 days after PDT may reflect the engagement
of activated macrophages in the elimination ofthe islets oftumour
cells remaining viable after the PDT treatment. Serving as profes-
sional antigen-presenting cells, macrophages can also secure
improved processing of tumour antigens and their presentation (in
the context ofMHC class II molecules) to helper T cells. Through
this activity, DBPMAF-activated macrophages would facilitate the
development ofT-cell-specific tumour immunity (Korbelik, 1996).
Another role ofDBPMAF in enhancing the destruction ofPDT-
treated tumours is suggested by the observation that the
immunopotentiation by DBPMAF overwhelmed the PDT-induced
immunosuppression (as demonstrated by the DTH response). In
accordance with the findings of other investigators (Elmets et al,
1986; Lynch et al, 1989), the treatment of SCCVII tumours by
PDT resulted in a markedly diminished DTH response in the
host animals. By blocking this immunosuppressive effect, the
DBPMAF therapy may have permitted a more pervasive tumour
destruction by PDT (Korbelik, 1996). Since macrophage activa-
tion for phagocytosis and subsequent antigen presentation is the
first step of the immune development process, the PDT-induced
immunosuppression was suggested to be related to the impairment
of macrophage activation by PDT (Yamamoto et al, 1992). The
adjuvant administration of DBPMAF bypasses the decapitated
macrophage activation cascade (Yamamoto et al, 1994) leading to
reversal ofthe immunosuppressive state.
The observed synergism ofPDT combined with DBPMAF treat-
ment provides direct evidence that PDT is highly receptive to the
adjuvant treatment with a macrophage-activating factor. This is
consistent with our earlier findings with the SCCVII carcinoma
model, which showed that the PDT response of this poorly
immunogenic tumour is enhanced by a combined treatment with
glucan SPG (Krosl and Korbelik, 1994) and cytokine granulo-
cyte-macrophage colony-stimulating factor (GM-CSF) (Krosl et
al, 1996); both these agents stimulate macrophage activity. On the
other hand, it was reported that the response of immunogenic
murine tumours to PDT is augmented by the adjuvant treatment
with BCG (Cho et al, 1992), Corynebacterium parvum vaccine
(Myers et al, 1989) or mycobacterial cell wall extract (Korbelik and
Krosl, 1996), which are also immune stimulants acting primarily
on macrophages. Together, these results raise the possibility that
PDT with adjuvant macrophage-directed immunotherapy may
eventually prove clinically useful for achieving improved control
ofsolid cancers.
ABBREVIATIONS
DBP, vitamin D3-binding protein; DBPMAF, vitamin D3-binding
protein-derived macrophage-activating factor; DNFB, 2,4-dinitro-
fluorobenzene; DTH, delayed-type contact hypersensitivity;
GcMAF, Gc protein-derived macrophage-activating factor; i.p.,
intraperitoneally; i.v., intravenously; mDBP, mouse DBP; PDT,
photodynamic therapy; p.t., peritumorally.
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